Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Rituximab Maintenance for Mantle Cell Lymphoma
This secondary analysis of the TRIANGLE trial investigated the efficacy and toxicity of rituximab maintenance added to ibrutinib-based regimens. Rituximab maintenance significantly
New Indication: Sacituzumab Govitecan Alone for Muscle-Invasive Bladder Cancer
The SURE-01 trial evaluated neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer. The study reported a ypT0N0 or ypT0Nx rate of 29.5% and a 24-month ev
New Reference: Trastuzumab Rezetecan for HER2+ Breast Cancer
Trastuzumab rezetecan significantly improved progression-free and overall survival compared to pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer w
New Reference: Zenocutumab for NRG1-Fusion Positive Cholangiocarcinoma
Zenocutuzumab demonstrated clinically meaningful and durable antitumor activity in patients with advanced NRG1-fusion positive cholangiocarcinoma, with an objective response rate o
New Protocol: Neoadjuvant Toripalimab with Celecoxib for MSI-H Colorectal Cancer
This randomized phase 2 study investigated the efficacy of neoadjuvant toripalimab plus celecoxib compared to toripalimab monotherapy in patients with dMMR or MSI-H locally advance
New Protocol: Talquetamab with Daratumumab for Rel/Ref Multiple Myeloma
In this phase 3 study, talquetamab plus daratumumab and pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) significantly improved progression-free and overall survival
New Protocol: Revumenib, Decitabine, and Venetoclax for Rel/Ref AML
This phase I-II study evaluated an all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia. The re
New Protocol: Polatuzumab with R-GemOx for Rel/Ref Large B-Cell Lymphoma
The POLARGO study demonstrated that Polatuzumab Vedotin plus Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) significantly improved overall survival and complete response ra
New Protocol: Pirtobrutinib with Venetoclax and Rituximab for CLL
In patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma, the addition of pirtobrutinib to venetoclax and rituximab significantly improved pro
